William Blair Comments on Biogen Inc.’s Q2 2017 Earnings (BIIB)
Biogen Inc. (NASDAQ:BIIB) – William Blair issued their Q2 2017 EPS estimates for Biogen in a report released on Monday. William Blair analyst M. Phipps forecasts that the biotechnology company will post earnings of $4.09 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Biogen’s Q3 2017 earnings at $5.30 EPS, Q4 2017 earnings at $5.34 EPS, FY2017 earnings at $19.93 EPS, FY2018 earnings at $22.51 EPS and FY2019 earnings at $24.58 EPS.
Several other research firms have also recently weighed in on BIIB. ValuEngine upgraded shares of Biogen from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Leerink Swann cut shares of Biogen from an “outperform” rating to a “market perform” rating and set a $300.00 price target on the stock. in a report on Thursday, March 16th. Vetr upgraded shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $310.17 price target on the stock in a report on Monday, March 20th. Mizuho cut their price target on shares of Biogen from $290.00 to $274.00 and set a “neutral” rating on the stock in a report on Wednesday, May 31st. Finally, Cantor Fitzgerald restated a “hold” rating and set a $277.00 price target on shares of Biogen in a report on Thursday, May 25th. Twelve analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $329.94.
WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/28/william-blair-comments-on-biogen-inc-s-q2-2017-earnings-biib.html.
Shares of Biogen (BIIB) opened at 271.25 on Wednesday. The company has a 50-day moving average of $256.84 and a 200 day moving average of $275.20. The firm has a market capitalization of $57.54 billion, a P/E ratio of 16.99 and a beta of 0.83. Biogen has a 52 week low of $223.02 and a 52 week high of $333.65.
Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, April 25th. The biotechnology company reported $5.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.97 by $0.23. Biogen had a net margin of 30.17% and a return on equity of 38.17%. The business had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period last year, the business posted $4.79 EPS. Biogen’s revenue was up 3.1% on a year-over-year basis.
A number of hedge funds have recently bought and sold shares of the company. Capital Guardian Trust Co. raised its stake in Biogen by 130.1% in the fourth quarter. Capital Guardian Trust Co. now owns 359 shares of the biotechnology company’s stock worth $102,000 after buying an additional 203 shares during the period. Pathstone Family Office LLC purchased a new stake in Biogen during the first quarter worth $102,000. Crestwood Advisors Group LLC purchased a new stake in Biogen during the first quarter worth $106,000. Harvest Fund Management Co. Ltd purchased a new stake in Biogen during the fourth quarter worth $110,000. Finally, Thompson Siegel & Walmsley LLC raised its stake in Biogen by 3.0% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 408 shares of the biotechnology company’s stock worth $116,000 after buying an additional 12 shares during the period. 87.39% of the stock is currently owned by institutional investors and hedge funds.
In related news, VP Paul J. Clancy sold 9,892 shares of the company’s stock in a transaction that occurred on Tuesday, April 25th. The shares were sold at an average price of $290.00, for a total transaction of $2,868,680.00. Following the sale, the vice president now owns 10,813 shares of the company’s stock, valued at approximately $3,135,770. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian S. Posner sold 1,084 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $256.31, for a total transaction of $277,840.04. Following the sale, the director now directly owns 6,330 shares in the company, valued at approximately $1,622,442.30. The disclosure for this sale can be found here. Insiders have sold a total of 12,957 shares of company stock worth $3,689,473 in the last ninety days. 0.32% of the stock is currently owned by insiders.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.